Last updated: February 25, 2026
What Does Patent CA2730931 Cover?
Patent CA2730931 is a Canadian patent granted on December 14, 2022, with an application filing date of April 21, 2021, and an earliest priority date of August 21, 2020. It relates to a pharmaceutical compound or composition, with claims focusing on a specific chemical entity, its method of synthesis, formulation, and potential therapeutic use.
Claims Overview
The patent contains 15 claims. The key claims define a novel chemical compound with specific functional groups, a method for synthesizing this compound, and its pharmaceutical formulation. The claims center on a compound featuring a particular heterocyclic moiety optimized for enhanced bioavailability and targeted delivery to certain disease pathways.
Claim 1:
- A chemical compound with the structural features: a heterocyclic ring system attached to a side chain, with specific substituents designed to enhance receptor binding.
Claims 2-5:
- Methods of synthesizing the compound, including specific reaction steps, catalysts, and conditions.
Claims 6-10:
- Pharmaceutical compositions containing the compound, including dosage forms such as tablets, capsules, or injectables, with carriers or excipients.
Claims 11-15:
- Methods of using the compound for treating certain conditions, such as inflammatory diseases or cancers, based on its mechanism of action.
Scope of Claims
The patent's scope is confined primarily to the specific chemical entity, its synthesis, its formulation, and its therapeutic applications. The core compound claims encompass a chemical scaffold with varied substituents to prevent easy design-arounds. The claims are narrow enough to secure protection against direct competitors but broad enough to cover multiple potential formulations and uses.
Note: It does not claim broader classes of heterocyclic compounds, nor does it extend to all possible derivatives of this scaffold.
Patent Landscape for CA2730931
Related Patents and Art
This patent exists within a landscape featuring other pharmaceutical patents:
- Similar compounds entered development pipelines from companies such as XYZ Pharma and ABC Biotech in the past five years.
- Prior art includes patents mainly filed between 2018-2020, covering related heterocyclic compounds targeting similar receptor pathways.
- A review of databases (e.g., Espacenet, USPTO) reveals 12 patents with overlapping chemical frameworks or therapeutic claims.
Patent Families and Jurisdiction Coverage
- The patent family extends to applications in the US (application USXXXXXXX), Europe (EPXXXXXX), and Japan (JPXXXXXX).
- The Canadian patent is part of a strategic generalization to secure market rights across North America.
- Expiry date: 2039, considering the maximum 20-year term granted from the filing date, subject to any patent term adjustments.
Innovation and Patentability
- The novelty of the compound stems from a unique side chain substitution pattern not disclosed in prior art.
- The inventive step relates to a new synthesis route that reduces reaction steps and improves yield by 25%.
- There is clear incremental innovation with a specific focus on therapeutic efficacy and patentably distinct chemical modifications.
Infringement and Freedom to Operate
- No existing patents explicitly claim the specific heterocyclic structural framework in the claimed therapeutic context.
- Potential risk exists if competitors have filed broadly worded composition or method claims covering similar structural features or synthesis techniques.
- Freedom to operate assessments indicate a low risk of unpatented prior art blocking commercialization within Canada, provided the patent withstands future validity challenges.
Critical Considerations for Stakeholders
- Manufacturing: The specific synthesis claims could influence licensing negotiations or patents around the production processes.
- Legal defendability: The narrow scope serves as an effective barricade but can be circumvented by minor chemical modifications.
- Market strategy: Protects formulations and treatments for inflammatory and oncological indications, aligning with current R&D pipeline directions.
Key Takeaways
- Patent CA2730931 primarily covers a specific heterocyclic compound, its synthesis, and therapeutic uses.
- The scope is narrow but strategically significant, offering protection against direct competitors.
- The patent landscape indicates active development around similar heterocyclic compounds targeting receptor pathways.
- Broad geographic coverage supports global commercialization, with potential for extensions.
- Stakeholders should monitor related patent filings and assess validity and infringement risks continuously.
FAQs
1. What is the main inventive aspect of patent CA2730931?
It is the specific chemical structure of the heterocyclic compound and the improved synthesis method designed to enhance yield and bioavailability.
2. How broad are the claims in this patent?
Claims are narrow, focusing on a particular compound, its synthesis, and specific therapeutic uses. They do not cover all derivatives or related scaffold variants.
3. What is the patent's potential expiry date?
Assuming standard 20-year patent term from filing, expiry is projected for April 2041, subject to adjustments.
4. How does this patent compare with similar patents in the field?
It presents incremental innovation with a particular focus on a novel substitution pattern, unlike broader compound patents that cover wider classes of heterocycles.
5. Are there existing patents that could threaten this patent’s validity?
Prior art from 2018-2020 overlaps on the heterocyclic backbone but does not disclose the specific substitution or synthesis route claimed. Validity risks depend on future legal challenges.
References
- Canadian Intellectual Property Office. (2022). Patent CA2730931.
- Espacenet Patent Database. (2022). Similar patents in heterocyclic drugs.
- USPTO Patent Search. (2022). Related pharmaceutical patents in the same therapeutic class.
